| Autor: |
Yamaguchi T; Department of Pharmacology, Showa University Graduate School of Pharmacy.; Pharmacological Research Center, Showa University., Shibata K; Department of Pharmacology, Showa University Graduate School of Pharmacy.; Pharmacological Research Center, Showa University., Hasumi K; Department of Applied Biological Science, Tokyo University of Agriculture and Technology., Nobe K; Department of Pharmacology, Showa University Graduate School of Pharmacy.; Pharmacological Research Center, Showa University. |
| Jazyk: |
angličtina |
| Zdroj: |
Biological & pharmaceutical bulletin [Biol Pharm Bull] 2024; Vol. 47 (2), pp. 434-442. |
| DOI: |
10.1248/bpb.b23-00771 |
| Abstrakt: |
Non-alcoholic steatohepatitis (NASH), which is on the rise due to the increasing obese population and changing lifestyles, causes fibrosis over time and carries the risk of progression to cirrhosis and hepatocellular carcinoma. However, there are no approved effective treatments for NASH. Recent studies suggest that increased lipid metabolism and reduced nitric oxide content are responsible for NASH; 3-amino-4-hydroxy benzoic acid (AHBA) was identified as an inhibitor for the phosphatase activity of soluble epoxy hydrolase, which in turn inhibits lipid metabolism and endothelial nitric oxide synthase activity. The aim of this study was to assess the efficacy of AHBA in a mouse model of NASH. NASH was induced in mice by streptozotocin administration and a high-fat diet loading. The efficacy of AHBA was determined by measuring liver function using serum and liver samples and conducting a morphological assessment. AHBA considerably attenuated the increase in the liver weight and alkaline phosphatase content, which occurred due to the progression of NASH. Hepatocellular steatosis, inflammatory cell infiltration, and hepatocellular ballooning of hepatocytes remained unaltered. In contrast, AHBA treatment significantly ameliorated the fibrotic alterations within liver tissue that were induced by the onset of NASH. These results demonstrate the potential of AHBA as a therapeutic pharmaceutical compound that can treat NASH. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
